Trends, patterns and relationship of antimicrobial use and resistance in bacterial isolates tested between 2015-2020 in a national referral hospital of Zambia

PLoS One. 2024 Apr 16;19(4):e0302053. doi: 10.1371/journal.pone.0302053. eCollection 2024.

Abstract

Increased antimicrobial resistance (AMR) among bacteria underscores the need to strengthen AMR surveillance and promote data-based prescribing. To evaluate trends and associations between antimicrobial usage (AMU) and AMR, we explored a dataset of 34,672 bacterial isolates collected between 2015 and 2020 from clinical samples at the University Teaching Hospital (UTH) in Lusaka, Zambia. The most frequently isolated species were Escherichia coli (4,986/34,672; 14.4%), Staphylococcus aureus (3,941/34,672; 11.4%), and Klebsiella pneumoniae (3,796/34,672; 10.9%). Of the 16 drugs (eight classes) tested, only amikacin and imipenem showed good (> 50%) antimicrobial activity against both E. coli and K. pneumoniae, while nitrofurantoin was effective only in E. coli. Furthermore, 38.8% (1,934/4,980) of E. coli and 52.4% (2,079/3,791) of K. pneumoniae isolates displayed multidrug resistance (MDR) patterns on antimicrobial susceptibility tests. Among S. aureus isolates, 44.6% (973/2,181) were classified as methicillin-resistant (MRSA). Notably, all the MRSA exhibited MDR patterns. The annual hospital AMR rates varied over time, while there was a weak positive relationship (r = 0.38, 95% CI = 0.11-0.60) between the monthly use of third-generation cephalosporins (3GCs) and 3GC resistance among Enterobacterales. Overall, the results revealed high AMR rates that fluctuated over time, with a weak positive relationship between 3GC use and resistance. To our knowledge, this is the first report to evaluate the association between AMU and AMR in Zambia. Our results highlight the need to strengthen antimicrobial stewardship programs and optimize AMU in hospital settings.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Anti-Infective Agents* / pharmacology
  • Drug Resistance, Bacterial
  • Escherichia coli
  • Hospitals
  • Humans
  • Klebsiella pneumoniae
  • Microbial Sensitivity Tests
  • Referral and Consultation
  • Staphylococcus aureus
  • Zambia / epidemiology

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents

Grants and funding

This research project was supported in part by a grant from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, for the Joint Research Program of the Hokkaido University International Institute for Zoonosis Control to YS, Japan Agency for Medical Research and Development (AMED) under Grant Number JP223fa627005 and JP22wm0125008 to YS, JSPS KAKENHI under Grant Number 21K15430 to AP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.